BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 19950291)

  • 1. Depletion of functionally active CD20+ T cells by rituximab treatment.
    Wilk E; Witte T; Marquardt N; Horvath T; Kalippke K; Scholz K; Wilke N; Schmidt RE; Jacobs R
    Arthritis Rheum; 2009 Dec; 60(12):3563-71. PubMed ID: 19950291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
    Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
    Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?
    Bar-Or A; Fawaz L; Fan B; Darlington PJ; Rieger A; Ghorayeb C; Calabresi PA; Waubant E; Hauser SL; Zhang J; Smith CH
    Ann Neurol; 2010 Apr; 67(4):452-61. PubMed ID: 20437580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-inflammatory effects of atorvastatin on peripheral blood mononuclear cells and synovial fibroblasts in rheumatoid arthritis.
    Blaschke S; Viereck V; Schwarz G; Klinger HM; Guerluek S; Müller GA
    Scand J Rheumatol; 2009; 38(4):235-9. PubMed ID: 19247848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry.
    Berner B; Akça D; Jung T; Muller GA; Reuss-Borst MA
    J Rheumatol; 2000 May; 27(5):1128-35. PubMed ID: 10813277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and function of inducible costimulator on peripheral blood T cells in patients with systemic lupus erythematosus.
    Yang JH; Zhang J; Cai Q; Zhao DB; Wang J; Guo PE; Liu L; Han XH; Shen Q
    Rheumatology (Oxford); 2005 Oct; 44(10):1245-54. PubMed ID: 15987711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid.
    van Amelsfort JM; Jacobs KM; Bijlsma JW; Lafeber FP; Taams LS
    Arthritis Rheum; 2004 Sep; 50(9):2775-85. PubMed ID: 15457445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-DR-binding Hsp60 self epitopes induce an interleukin-10-mediated immune response in rheumatoid arthritis.
    de Jong H; Lafeber FF; de Jager W; Haverkamp MH; Kuis W; Bijlsma JW; Prakken BJ; Albani S
    Arthritis Rheum; 2009 Jul; 60(7):1966-76. PubMed ID: 19565483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.
    Roll P; Palanichamy A; Kneitz C; Dorner T; Tony HP
    Arthritis Rheum; 2006 Aug; 54(8):2377-86. PubMed ID: 16869000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of A2A extracellular adenosine receptor expression in different functional subsets of human peripheral T cells. Flow cytometry studies with anti-A2A receptor monoclonal antibodies.
    Koshiba M; Rosin DL; Hayashi N; Linden J; Sitkovsky MV
    Mol Pharmacol; 1999 Mar; 55(3):614-24. PubMed ID: 10051547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.
    Leandro MJ; Cambridge G; Ehrenstein MR; Edwards JC
    Arthritis Rheum; 2006 Feb; 54(2):613-20. PubMed ID: 16447239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
    Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
    Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia.
    Theyer G; Kramer G; Assmann I; Sherwood E; Preinfalk W; Marberger M; Zechner O; Steiner GE
    Lab Invest; 1992 Jan; 66(1):96-107. PubMed ID: 1370561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells partially abrogate the regulatory activity of CD4+CD25+ T cells present in the human peripheral blood.
    Ahn JS; Krishnadas DK; Agrawal B
    Int Immunol; 2007 Mar; 19(3):227-37. PubMed ID: 17289657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expansion of peripheral CD8+ CD28- T cells in response to Epstein-Barr virus in patients with rheumatoid arthritis.
    Klatt T; Ouyang Q; Flad T; Koetter I; Bühring HJ; Kalbacher H; Pawelec G; Müller CA
    J Rheumatol; 2005 Feb; 32(2):239-51. PubMed ID: 15693083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptotic effect of rituximab on peripheral blood B cells in rheumatoid arthritis.
    Szodoray P; Alex P; Dandapani V; Nakken B; Pesina J; Kim X; Wallis GL; Wilson PC; Jonsson R; Centola M
    Scand J Immunol; 2004; 60(1-2):209-18. PubMed ID: 15238091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes.
    Hultin LE; Hausner MA; Hultin PM; Giorgi JV
    Cytometry; 1993; 14(2):196-204. PubMed ID: 7679964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms.
    Voso MT; Pantel G; Rutella S; Weis M; D'Alò F; Urbano R; Leone G; Haas R; Hohaus S
    Haematologica; 2002 Sep; 87(9):918-25. PubMed ID: 12217803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis.
    Raptopoulou AP; Bertsias G; Makrygiannakis D; Verginis P; Kritikos I; Tzardi M; Klareskog L; Catrina AI; Sidiropoulos P; Boumpas DT
    Arthritis Rheum; 2010 Jul; 62(7):1870-80. PubMed ID: 20506224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
    Li J; Davis J; Bracht M; Carton J; Armstrong J; Gao W; Scallon B; Fung R; Emmell E; Zimmerman M; Griswold DE; Li L
    Int Immunopharmacol; 2006 Jun; 6(6):880-91. PubMed ID: 16644473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.